CART Newsletter
Spring 2011
Spring 2012
Spring 2013

Study of Guanfacine and Methylphenidate for the Treatment of Hyperactivity in Pervasive Developmental Disorder (PDD)

Study Detail

The purpose of this study is to learn if a study drug called Guanfacine is helpful in

treating hyperactivity and impulsiveness in children with PDD. Guanfacine is widely

used for the treatment of hyperactivity and impulsiveness in this population, but has not

been carefully studied. It is approved by the FDA for the treatment of hypertension, but a

long-acting formula has recently been approved to treat Attention-Deficit/Hyperactivity

Disorder in children. This study will also determine if adding methylphenidate (MPH) on

top of guanfacine will improve hyperactive and impulsive symptoms in children who are

not responding positively to guanfacine alone. MPH is FDA approved for the treatment

of these symptoms in children.

 

Project: 
Study of Guanfacine and Methylphenidate for the Treatment of Hyperactivity in Pervasive Developmental Disorder (PDD)
More information and application
Target audience: 

Youth diagnosed with an Autism Spectrum Disorder between the ages of 5 and 14 years with high levels of Hyperactive or Impulsive Behavior.

Involvement: 

Participants will recieve Guanfacine or placebo (some children may also receive methylphenidate).  Youth selected for the study will participate in questionnaires, interviews, psychological and laboratory testing.

Benefits: 

Eligible youth will receive $25 for each study visit.

Contact details: 

For more information, please call UCLA at (310) 794-2215.

Review and Approval
IRB Flyer: 
application/pdf iconMcCracken_Guanfacine 2.8.13.pdf
Renewal Date: 
2013, February 8

  • Printer-friendly version
  • share